

# CANCER GENOMICS & PROTEOMICS

**Published by the International Institute of Anticancer Research**

ISSN (print): 1109-6535; ISSN (online): 1790-6245

**Volume 12, 2015**

**INDEX**

*This volume is dedicated to the memory of*  
*B.F.C. CLARK*

## Editorial Board

<b>A. Seth</b>	Editor-in-Chief Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
<b>J.G. Delinasios</b>	Managing Editor and Executive Publisher International Institute of Anticancer Research, Athens, Greece
<b>L.A. Aaltonen</b>	Department of Medical Genetics, University of Helsinki, Finland
<b>R. Abagyan</b>	The Scripps Research Institute, La Jolla, CA, USA
<b>F. Ahmed</b>	Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
<b>D.-T. Bau</b>	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan
<b>B.F.C. Clark</b>	Department of Molecular Biology, University of Aarhus, Denmark
<b>R. Clarke</b>	Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
<b>T. Efferth</b>	Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
<b>J.A. Fernandes-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>C.V. Forst</b>	Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
<b>D.S. Gerhard</b>	NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
<b>T.R. Golub</b>	Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
<b>J. Gordon</b>	Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
<b>J.W. Gray</b>	OHSU Knight Cancer Institute, Biomedical Engineering, Portland, OR, USA
<b>C.-H. Heldin</b>	Ludwig Institute for Cancer Research, Uppsala, Sweden
<b>J.D. Hoheisel</b>	Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
<b>R.P. Huang</b>	RayBiotech, Inc., Norcross, GA, USA
<b>T.H.M. Huang</b>	Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
<b>S.C. Jhanwar</b>	Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
<b>W.G. Jiang</b>	Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, UK
<b>V.C. Jordan</b>	Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA
<b>J. Ju</b>	Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
<b>A. Kallioniemi</b>	Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
<b>O.P. Kallioniemi</b>	Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
<b>K. Khalili</b>	College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
<b>D.G. Kieback</b>	Department of Obstetrics and Gynecology, Elblandklinikum, Riesa (Dresden), Germany
<b>S.D. Kottaridis</b>	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
<b>Y. T. Kwon</b>	Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea
<b>B. Léylund-Jones</b>	Avera Cancer Institute, Sioux Falls, SD, USA
<b>P. Lichter</b>	Deutsches Krebsforschungszentrum, Heidelberg, Germany
<b>A. Lindblom</b>	Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
<b>G. Lubec</b>	Department of Pediatrics, University of Vienna, Austria
<b>J. Lyons-Weiler</b>	Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
<b>P.J. McCormick</b>	The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
<b>J.D. Minna</b>	Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
<b>F. Mitelman</b>	Department of Clinical Genetics, University Hospital, Lund, Sweden
<b>C. Nicot</b>	Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA

<b>L. O'Driscoll</b>	School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
<b>I. Pastan</b>	Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA
<b>C.D. Platsoucas</b>	College of Sciences, Old Dominion University, Norfolk, VA, USA
<b>J. Quackenbush</b>	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
<b>J.S. Rader</b>	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
<b>R.H. Reeves</b>	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
<b>K.L. Reichelt</b>	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
<b>T. Ried</b>	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
<b>G. Rimbach</b>	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
<b>K.D. Rodland</b>	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
<b>C. Sansom</b>	The School of Crystallography, Birbeck College, University of London, UK
<b>N.A. Saunders</b>	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
<b>B.W. Schäfer</b>	Department of Oncology, University Children's Hospital, Zurich, Switzerland
<b>J. Schneider</b>	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
<b>O.J. Semmes</b>	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
<b>G.V. Sherbet</b>	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
<b>S. Smith</b>	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
<b>J.C. Strefford</b>	Cancer Science Division, Southampton General Hospital, Southampton, UK
<b>J.M. Trent</b>	Tgen, Phoenix, AZ, USA
<b>G. Tsangaris</b>	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
<b>L.-C. Tsui</b>	University of Hong Kong, Hong Kong
<b>G.F. Vande Woude</b>	Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
<b>D.K. Watson</b>	Department of Pathology & Laboratory Medicine, The James E. Clyburn Research Center, Medical University of South Carolina, Charleston, SC, USA
<b>U.H. Weidle</b>	Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
<b>A.T. Yeung</b>	Fox Chase Cancer Center, Philadelphia, PA, USA
<b>H. Zhang</b>	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index Expanded (Web of Science); Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. Web: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.cgp.iijournals.org](http://www.cgp.iijournals.org).

**Editorial Office in U.S.A.:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlights, NJ 07732, USA.

E-mail: [journals@iia-anticancer.org](mailto:journals@iia-anticancer.org). Managing Editor: [editor@iia-anticancer.org](mailto:editor@iia-anticancer.org).

Web: [www.iia-anticancer.org](http://www.iia-anticancer.org); [www.cgp.iijournals.org](http://www.cgp.iijournals.org).

Manuscripts and correspondence should be addressed to: Dr. John G. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: [editor@iia-anticancer.org](mailto:editor@iia-anticancer.org)

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

## Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 12, 2015.

Albert Hung Foundation, Hong Kong, P.R. China  
ANNALAB Laboratory, Pittsburgh, PA, U.S.A.

Bloomington Stock Center, Bloomington, IN, U.S.A.

Cancer Research Wales, Cardiff, U.K.  
Cancer Science Institute of Singapore, Singapore  
Cardiff University's China Medical Scholarship., Cardiff, U.K.

Chang Gung Memorial Hospital, Taiwan R.O.C.  
Chulabhorn Research Institute, Bangkok, Thailand  
Conference of Rectors of Universities of Switzerland (CRUS), Switzerland

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília, Brazil  
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, Brazil

Danish Cancer Society, Copenhagen, Denmark  
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark  
Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany  
Duke-NUS Graduate Medical School (Duke-NUS), Singapore

European Regional Development Fund (ERDF), Brussels, Belgium  
European Social Fund (ESF), European Commission, Brussels, Belgium

FACS Sorting Core Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany  
FIRB/MERIT Project, Italy  
Florida Atlantic University Foundation, Inc., Boca Raton, FL, U.S.A  
Forschungs- und Wissenschaftsstiftung Hamburg, Landesexzellenzinitiative (LEXI), Hamburg, Germany  
Forschungsförderung Medizin, Medical Faculty of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany  
Fundação Araucária, Curitiba, Brazil  
Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Belo Horizonte, Brazil

Gene Research Centre, Yamaguchi University, Yamaguchi, Japan  
GeneCards, Weizmann Institute of Science, Rehovot, Israel

Helmholtz Association of German Research Centres, Germany  
Hospital de Clínicas, Curitiba, Brazil  
Hospital Nossa Senhora das Graças, Joinville, Brazil  
Human Proteome Map and ProteomesDB, Walldorf, Germany

Institute for Breathing and Sleep (IBAS), Heidelberg, VIC, Australia  
International Cooperation Program for Excellent Lecturers, Shandong University, P.R. China  
Italian Ministry of University and Research (MIUR) Grant, Italy

Kolker Laboratory, MOPED Team, Seattle Children's Hospital, Research & Foundation, Seattle, WA, U.S.A.

Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan  
Ministry of Education, Universities and Research, Italy  
Ministry of Health and Welfare of the Republic of China, Taipei City, Taiwan, R.O.C.  
Ministry of Science and Technology, Taipei City, Taiwan, R.O.C.

National Cancer Centre, Singapore  
National Research Foundation of Korea Grant, Republic of Korea  
National Science and Technology Development Agency, Bangkok, Thailand

School of Medical Sciences, RMIT University, Bundoora, VIC, Australia  
SRL Inc., Tokyo, Japan  
Swiss National Science Foundation (SNSF), Berne, Switzerland

Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.  
Universidade Federal do Paraná, Curitiba, Brazil  
University of South Florida Research Computing, Tampa, FL, U.S.A.

Vienna *Drosophila* RNAi Center (VDRC), Vienna, Austria  
Virtual Institute MetBioMat, Germany

Welsh Life Science Fund, Wales, U.K.

Yiling Foundation, P.R. China

## Contents, Volume 12, 2015

### Number 1

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YAN, W.G. JIANG ( <i>Beijing, PR China; Cardiff, UK</i> ) .....	1
Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN ( <i>Boca Raton, FL, USA</i> ) .....	9
Epigenetic Silencing of <i>GNMT</i> Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU ( <i>Bucharest, Romania; Charlestown, MA, USA</i> ) .....	21
Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in <i>EGFR</i> -mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA ( <i>Tokyo, Japan</i> ) .....	31
Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROOD, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS ( <i>Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia</i> ) .....	39

### Number 2

Isolation of a Growth Factor Stress-induced Pancreatic Cancer Sub-population: Insight into Changes Due to Micro-environment. B. BARON, T. KITAGAWA, K. NAKAMURA, Y. KURAMITSU ( <i>Msida, Malta; Yamaguchi; Shunan-shi, Japan</i> ) .....	49
Results, Questions, Perspectives of a Study on Human Polyomavirus BK and Molecular Actors in Prostate Cancer Development. M. MISCHITELLI, A. BELLIZZI, E. ANZIVINO, D.M. RODIO, A. SCIARRA, V. GENTILE, V. PIETROPAOLO ( <i>Rome; Foggia, Italy; Philadelphia, PA, USA</i> ) .....	57
Assessment of the Association Between Micronuclei and the Degree of Uterine Lesions and Viral Load in Women with Human Papillomavirus. M.L. ADAM, C. PINI, S. TÚLIO, J.C. LAPENDA LINS CANTALICE, R.A. TORRES, M.T.D.S. CORREIA ( <i>Pernambuco; Curitiba, Paraná, Brazil</i> ) .....	67
Cigarette Smoke-induced Effects on The Cell Cycle in Oral Cancer Cells: Reduction of G2/M Fraction. E. KRAYZLER, R.M. NAGLER ( <i>Haifa, Israel</i> ) .....	73
DNA Fragmentation Induced by Cigarette Smoke in Oral Cancer Cells. R.M. NAGLER, E. KRAYZLER, L. VEENMAN, M. GAVISH ( <i>Haifa, Israel</i> ) .....	77
Comparative Proteomic Analysis of Two Stress-management Strategies in Pancreatic Cancer. B. BARON, T. FUJIOKA, T. KITAGAWA, S.-I. MAEHARA, Y. MAEHARA, K. NAKAMURA, Y. KURAMITSU ( <i>Msida, Malta; Yamaguchi; Shunan-shi; Fukuoka, Japan</i> ) .....	83
Comparative Proteomics of Primary Breast Carcinomas and Lymph Node Metastases Outlining Markers of Tumor Invasion. H.H. MILIOLI, K.S. SOUSA, R. KAVISKI, N.C.D.S. OLIVEIRA, C.D.A. URBAN, R.S. DE LIMA, I.J. CAVALLI, E.M.D.S.F. RIBEIRO ( <i>Curitiba, Brazil</i> ) .....	89

**Number 3**

- Transcriptomic Profiling of Forkhead Box Transcription Factors in Adult Glioblastoma Multiforme. E. ROBERTSON, C. PERRY, R. DOHERTY, S. MADHUSUDAN (*Nottingham, UK*) ..... 103
- Expression of Metastasis-associated Gene-1 Is Associated With Bone Invasion and Tumor Stage in Human Pituitary Adenomas. W. JIA, J. ZHU, T.A. MARTIN, A.J. SANDERS, X. YANG, S. CHENG, H. YU, G. JIA, X. LIU, R. LU, W.G. JIANG (*Beijing; Yantai, Shandong, PR China; Cardiff, UK*) ..... 113
- Druggable Cancer Secretome: Neoplasm-associated Traits. R. NARAYANAN (*Boca Raton, FL, USA*) ..... 119
- Effect of STAT3 Inhibition on the Metabolic Switch in a Highly STAT3-activated Lymphoma Cell Line. Y. AKIYAMA, A. IIZUKA, A. KUME, M. KOMIYAMA, K. URAKAMI, T. ASHIZAWA, H. MIYATA, M. OMIYA, M. KUSUHARA, K. YAMAGUCHI (*Shizuoka, Japan*) ..... 133
- \* Review: Caveolin-1, Breast Cancer and Ionizing Radiation. M. PUCCI, V. BRAVATÀ, G.I. FORTE, F.P. CAMMARATA, C. MESSA, M.C. GILARDI, L. MINAFRA (*Cefalù; Milan; Monza, Italy*) ..... 143
- Topological Network Analysis of Differentially Expressed Genes in Cancer Cells with Acquired Gefitinib Resistance. Y.S. LEE, S.G. HWANG, J.K. KIM, T.H. PARK, Y.R. KIM, H.S. MYEONG, K. KWON, C.S. JANG, Y.H. NOH, S.Y. KIM (*Seoul; Chuncheon; Yangsan, Republic of Korea*) ..... 153

**Number 4**

- The Blood–Brain Barrier Challenge for the Treatment of Brain Cancer, Secondary Brain Metastases, and Neurological Diseases. U.H. WEIDLE, J. NIEWÖHNER, G. TIEFENTHALER (*Penzberg, Germany*) ..... 167
- Combined Application of RGB Marking and Mass Spectrometric Imaging Facilitates Detection of Tumor Heterogeneity. P. ABRAMOWSKI, O. KRAUS, S. ROHN, K. RIECKEN, B. FEHSE, H. SCHLÜTER (*Hamburg, Germany*) ..... 179
- High Frequency of JCV DNA Detection in Prostate Cancer Tissues. E. ANZIVINO, D.M. RODIO, M. MISCHITELLI, A. BELLIZZI, A. SCIARRA, S. SALCICCIA, V. GENTILE, V. PIETROPAOLO (*Rome, Italy; Philadelphia, PA, USA*) ..... 189
- Proteomic Analysis Reveals Aberrant O-GlcNAcylation of Extracellular Proteins from Breast Cancer Cell Secretion. P. NETSIRISAWAN, D. CHOKCHAICHAMNANKIT, C. SRISOMSAP, J. SVASTI, V. CHAMPATTANACHAI (*Bangkok, Thailand*) ..... 201

**Number 5**

- Interleukin 21 and Its Receptor Play a Role in Proliferation, Migration and Invasion of Breast Cancer Cells. L.-N. WANG, Y.-X. CUI, F. RUGE, W.G. JIANG (*Cardiff, UK; Weifang, Shandong, PR China*) ..... 211
- Circulating Messenger RNA Profiling with Microarray and Nextgeneration Sequencing: Cross-platform Comparison. C.-L. SHIH, J.-D. LUO, J.W.-C. CHANG, T.-L. CHEN, Y.-T. CHIEN, C.-J. YU, C.-C. CHIOU (*Taoyuan, Taiwan, ROC*) ..... 223
- Gene-expression Profiling in Non-small Cell Lung Cancer with Invasion of Mediastinal Lymph Nodes for Prognosis Evaluation. M. GRIGOROIU, R. TAGETT, S. DRAGHICI, S. DIMA, A. NASTASE, R. FLOREA, A. SOROP, V. ILIE, N. BACALBASA, V. TICA, V. LASZLO, A. MANSUET-LUPO, D. DAMOTTE, W. KLEPETKO, I. POPESCU, J.F. REGNARD (*Bucharest, Romania; Detroit, MI, USA; Paris, France; Vienna, Austria*) ..... 231

Interleukin-24 (IL-24) Expression and Biological Impact on HECV Endothelial Cells. Y. TAN, A.J. SANDERS, Y. ZHANG, T.A. MARTIN, S. OWEN, F. RUGE, W.G. JIANG ( <i>Cardiff, UK; Zibo, Shandong, PR China</i> ) .....	243
Comparative Proteomics of Tumor and Paired Normal Breast Tissue Highlights Potential Biomarkers in Breast Cancer. G.G. DA COSTA, T.H.B. GOMIG, R. KAVISKI, K.S. SOUSA, C. KUKOLJ, R.S. DE LIMA, C. DE ANDRADE URBAN, I.J. CAVALLI, E.M.S.F. RIBEIRO ( <i>Curitiba, Brazil</i> ) .....	251
Impact of PTEN IVS4 Polymorphism (rs3830675) on Cancer Susceptibility: An Updated Meta-analysis. Y. WANG, H. YANG, J. LUO, J. GE ( <i>Shenyang, Liaoning, PR China; San Francisco, CA, USA</i> ) .....	263
<b>Number 6</b>	
Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma. X. LAI, S. CHEN ( <i>Indianapolis, IN, USA</i> ) .....	271
A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. T.J. FAWCETT, M.L. PARRY, G. BLANCK ( <i>Tampa, FL, USA</i> ) .....	283
* Review: Ensuring Sample Quality for Biomarker Discovery Studies – Use of ICT Tools to Trace Biosample Life-cycle. S. RIONDINO, P. FERRONI, A. SPILA, J. ALESSANDRONI, R. D’ALESSANDRO, V. FORMICA, D. DELLA-MORTE, R. PALMIROTTA, U. NANNI, M. ROSELLI, F. GUADAGNI ( <i>Rome, Italy</i> ) .....	291
Oligo-based High-resolution aCGH Analysis Enhances Routine Cytogenetic Diagnostics in Haematological Malignancies. E. KJELDSEN ( <i>Aarhus, Denmark</i> ).....	301
<i>MTAI</i> Is Up-regulated in Colorectal Cancer and Is Inversely Correlated with Lymphatic Metastasis. J. LI, L. YE, P.-H. SUN, L. SATHERLEY, R. HARGEST, Z. ZHANG, W.G. JIANG ( <i>Cardiff, UK; Beijing, PR China</i> ) .....	339
Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells. M. PETROVIC, C. SIMILLION, P. KRUZLIAK, J. SABO, M. HELLER ( <i>Kosice, Slovak Republic; Bern, Switzerland; Brno, Czech Republic</i> ) .....	347
Contribution of DNA Double-strand Break Repair Gene <i>XRCC3</i> Genotypes to Triple-negative Breast Cancer Risk. C.-H. SU, W.-S. CHANG, P.-S. HU, C.-L. HSIAO, H.-X. JI, C.-H. LIAO, T.-C. YUEH, C.-L. CHUANG, C.-W. TSAI, C.-M. HSU, H.-Y. LANE, D.-T. BAU ( <i>Taichung; Changhua; Taipei, Taiwan, ROC</i> ) .....	359
Global Proteomic Profiling of <i>Drosophila</i> Ovary: A High-resolution, Unbiased, Accurate and Multifaceted Analysis. A.D. VELENTZAS, A.K. ANAGNOSTOPOULOS, P.D. VELENTZAS, V.E. MPAKOU, N.E. SAGIOGLOU, M.M. TSIOKA, S. KATARACHIA, A.K. MANTA, E.G. KONSTANTAKOU, I.S. PAPASSIDERI, G.T. TSANGARIS, D.J. STRAVOPODIS ( <i>Athens, Greece</i> ) .....	369
* Review: Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer. F. LUMACHI, G.B. CHIARA, L. FOLTRAN, S.M.M. BASSO ( <i>Padova; Pordenone, Italy</i> ) .....	385
Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. S. SUGIE, S. MUKAI, K. YAMASAKI, T. KAMIBEPPU, H. TSUKINO, T. KAMOTO ( <i>Miyazaki, Japan</i> ) .....	391
Cytotoxic Activities of Eosinophil Cationic Protein and Eosinophil-derived Neurotoxin: <i>In Silico</i> Analysis. P.C.R. DE OLIVEIRA, D.D.O. LOPES, I.E.D.V. COELHO, M.C. PEREIRA ( <i>Divinópolis, Brazil</i> ) .....	397
Index .....	403

Reviews in Volume 12, pages: 143, 291, 385.



## Subject Index

(Figures refer to page numbers)

- 2D PAGE, proteomics, breast cancer, lymph node, metastasis, markers, MALDI-ToF, mass spectrometry, tumour invasion, 89
- ACGH, haematological malignancy, karyotyping, FISH, chromothripsis, 301
- Acquired drug resistance, meta-analysis, microarray, differentially expressed genes, DEGs, gefitinib, 153
- Adenoma, biomarker, follicular, mass spectrometry, therapeutic target, 271
- Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Animal metastasis models, antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, transferrin receptor, insulin receptor, receptor-mediated endocytosis, molecular Trojan horses, review, 167
- Antibody-antibody fusion, antibody-effector protein fusion, tropism of metastasis, transferrin receptor, insulin receptor, animal metastasis models, receptor-mediated endocytosis, molecular Trojan horses, review, 167
- Antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, transferrin receptor, insulin receptor, animal metastasis models, receptor-mediated endocytosis, molecular Trojan horses, review, 167
- Apoptosis, oral cancer, cigarette smoke, 77
- Apoptosis, oral cancer, cigarette smoke, cell cycle, 73
- BALF, lung adenocarcinoma, mass spectrophotometry, quantitative proteomics, protein, biomarker, 39
- Biobanking, biomarker discovery, ICT tools, sample quality, review, 291
- Bioinformatics, *Drosophila*, liquid chromatography, mass spectrometry, ovary, proteome, proteomics, 369
- Bioinformatics, eosinophil cationic protein, eosinophil-derived neurotoxin, homology, post-translational modifications, 397
- Biomarker discovery, biobanking, ICT tools, sample quality, review, 291
- Biomarker identification, breast cancer, proteome, differential expression, 251
- Biomarker, adenoma, follicular, mass spectrometry, therapeutic target, 271
- Biomarker, CAV1, breast cancer, ionizing radiation, review, 143
- Biomarker, lung adenocarcinoma, mass spectrophotometry, quantitative proteomics, BALF, protein, 39
- Biomarkers, Alzheimer's disease, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- BKV infected prostate cells, prostate cancer development, oncogenes, human Polyomavirus BK, p53 mutational rate, 57
- BKV, prostate cancer, JCV, NCCR, sequence analysis, 189
- Body fluids, Alzheimer's disease, biomarkers, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Body fluids, biomarkers, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Bone invasion, *MTA1*, pituitary adenoma, staging, sella destruction, 113
- Breast cancer, CAV1, biomarker, ionizing radiation, review, 143
- Breast cancer, doxorubicin, chemotherapy, side-effects, PAcIFIC, LC-MS/MS, pathway analysis, chemo brain, neuronal pathway down-regulation, 347
- Breast cancer, extracellular proteins, heat-shock 70 kDa, *O*-GlcNAcylation, transitional endoplasmic reticulum ATPase, 201
- Breast cancer, IL21, IL21 receptor, survival, migration, invasion, 211
- Breast cancer, proteome, differential expression, biomarker identification, 251
- Breast cancer, proteomics, genomics, early breast cancer, targeted therapies, HER2, triple-negative, VEGF, trastuzumab, mTOR, review, 385
- Breast cancer, proteomics, lymph node, metastasis, markers, 2D PAGE, MALDI-ToF, mass spectrometry, tumour invasion, 89
- Cancer metabolomics, STAT3, shRNA, Warburg effect, proteomics, 133
- Cancer sub-population, pancreatic cancer, micro-environment, proteomics, 49
- Cancer, PTEN, polymorphism, meta-analysis, 263
- CAV1, breast cancer, biomarker, ionizing radiation, review, 143
- Caveolin-1, caveolin-2, prostate cancer progression, 391
- Caveolin-2, caveolin-1, prostate cancer progression, 391
- Cell cycle, oral cancer, cigarette smoke, apoptosis, 73
- Chemo brain, doxorubicin, chemotherapy, side-effects, PAcIFIC, LC-MS/MS, breast cancer, pathway analysis, neuronal pathway down-regulation, 347

- Chemogenomics, biomarkers, body fluids, chemoinformatics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Chemoinformatics, biomarkers, body fluids, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Chemotherapy, doxorubicin, side-effects, PAcIFIC, LC-MS/MS, breast cancer, pathway analysis, chemo brain, neuronal pathway down-regulation, 347
- Chromothripsis, haematological malignancy, karyotyping, FISH, aCGH, 301
- Cigarette smoke, oral cancer, apoptosis, 77
- Cigarette smoke, oral cancer, cell cycle, apoptosis, 73
- Circulating mRNA, RNA sequencing, DASL assay, transcriptomic profiling, 223
- Claudin-1, claudin-5, claudin-16, clear cell renal cell carcinoma, paracellular permeability, 1
- Claudin-16, Claudin-1, claudin-5, clear cell renal cell carcinoma, paracellular permeability, 1
- Claudin-5, Claudin-1, claudin-16, clear cell renal cell carcinoma, paracellular permeability, 1
- Clear cell renal cell carcinoma, Claudin-1, claudin-5, claudin-16, paracellular permeability, 1
- Clinical variations, Alzheimer's disease, biomarkers, body fluids, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Clinical variations, biomarkers, body fluids, chemoinformatics, chemogenomics, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Colorectal carcinoma, *MTA1*, *VEGFC*, lymphatic metastasis, 339
- Cytoskeletal proteins, TCGA, mutation density, oncoproteins, tumor suppressor proteins, mutation frequency, 283
- Dark matter proteome, Alzheimer's disease, biomarkers, body fluids, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- DASL assay, circulating mRNA, RNA sequencing, transcriptomic profiling, 223
- DEGs, meta-analysis, microarray, differentially expressed genes, acquired drug resistance, gefitinib, 153
- Differential expression, breast cancer, proteome, biomarker identification, 251
- Differentially expressed genes, meta-analysis, microarray, DEGs, acquired drug resistance, gefitinib, 153
- Digital PCR, non-small-cell lung cancer, epidermal growth factor receptor tyrosine kinase inhibitor, T790M, 31
- DNA damage, HPV, uterine lesions, viral load, micronuclei, 67
- Doxorubicin, chemotherapy, side-effects, PAcIFIC, LC-MS/MS, breast cancer, pathway analysis, chemo brain, neuronal pathway down-regulation, 347
- Drosophila*, bioinformatics, liquid chromatography, mass spectrometry, ovary, proteome, proteomics, 369
- Druggable targets, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Druggable targets, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Early breast cancer, proteomics, genomics, breast cancer, targeted therapies, HER2, triple-negative, VEGF, trastuzumab, mTOR, review, 385
- Endothelial cell, IL-24, MDA-7, HECV, 243
- Eosinophil cationic protein, eosinophil-derived neurotoxin, homology, bioinformatics, post-translational modifications, 397
- Eosinophil-derived neurotoxin, eosinophil cationic protein, homology, bioinformatics, post-translational modifications, 397
- Epidermal growth factor receptor tyrosine kinase inhibitor, digital PCR, non-small-cell lung cancer, T790M, 31
- Epigenetic alteration, promoter methylation, pancreatic cancer, 21
- Expression quantitative loci, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Expression quantitative loci, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Extracellular proteins, breast cancer, heat-shock 70 kDa, *O*-GlcNAcylation, transitional endoplasmic reticulum ATPase, 201
- FISH, haematological malignancy, karyotyping, aCGH, chromothripsis, 301
- Follicular, adenoma, biomarker, mass spectrometry, therapeutic target, 271
- FOX transcription factors, glioblastoma multiforme, prognostic factor, predictive factor, 103
- Gefitinib, meta-analysis, microarray, differentially expressed genes, DEGs, acquired drug resistance, 153
- Gene ontology, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9

- Gene ontology, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Gene signature, microarray, non-small cell lung cancer, 231
- Genome-wide association studies, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Genome-wide association studies, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Genomics, proteomics, breast cancer, early breast cancer, targeted therapies, HER2, triple-negative, VEGF, trastuzumab, mTOR, review, 385
- Genotype, menarche, menopause, triple-negative breast cancer, *XRCC3*, 359
- Glioblastoma multiforme, FOX transcription factors, prognostic factor, predictive factor, 103
- Haematological malignancy, karyotyping, FISH, aCGH, chromothripsis, 301
- Heat-shock 70 kDa, breast cancer, extracellular proteins, O-GlcNAcylation, transitional endoplasmic reticulum ATPase, 201
- HECV, IL-24, MDA-7, endothelial cell, 243
- HER2, proteomics, genomics, breast cancer, early breast cancer, targeted therapies, triple-negative, VEGF, trastuzumab, mTOR, review, 385
- Homology, eosinophil cationic protein, eosinophil-derived neurotoxin, bioinformatics, post-translational modifications, 397
- HPV, uterine lesions, viral load, DNA damage, micronuclei, 67
- Human Polyomavirus BK, prostate cancer development, oncogenes, p53 mutational rate, BKV infected prostate cells, 57
- ICT tools, biomarker discovery, biobanking, sample quality, review, 291
- IL21 receptor, IL21, breast cancer, survival, migration, invasion, 211
- IL21, IL21 receptor, breast cancer, survival, migration, invasion, 211
- IL-24, MDA-7, endothelial cell, HECV, 243
- Insulin receptor, antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, transferrin receptor, animal metastasis models, receptor-mediated endocytosis, molecular Trojan horses, review, 167
- Invasion, IL21, IL21 receptor, breast cancer, survival, migration, 211
- Ionizing radiation, CAV1, breast cancer, biomarker, review, 143
- JCV, prostate cancer, BKV, NCCR, sequence analysis, 189
- Karyotyping, haematological malignancy, FISH, aCGH, chromothripsis, 301
- LC-MS/MS, doxorubicin, chemotherapy, side-effects, PACIFIC, breast cancer, pathway analysis, chemo brain, neuronal pathway down-regulation, 347
- Lentiviral vectors, mass spectrometric imaging, MSI, tumor heterogeneity, RGB marking, proteomics, 179
- Leukemia and lymphoma, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Leukemia and lymphoma, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, open reading frames, phenome-genome association, secretome, rule of five, tumors, 119
- Liquid chromatography, bioinformatics, *Drosophila*, mass spectrometry, ovary, proteome, proteomics, 369
- Lung adenocarcinoma, mass spectrophotometry, quantitative proteomics, BALF, protein, biomarker, 39
- Lymph node, proteomics, breast cancer, metastasis, markers, 2D PAGE, MALDI-ToF, mass spectrometry, tumour invasion, 89
- Lymphatic metastasis, *MTAI*, *VEGFC*, colorectal carcinoma, 339
- MALDI-ToF, proteomics, breast cancer, lymph node, metastasis, markers, 2D PAGE, mass spectrometry, tumour invasion, 89
- Malignant melanoma, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, neuroblastoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Markers, proteomics, breast cancer, lymph node, metastasis, 2D PAGE, MALDI-ToF, mass spectrometry, tumour invasion, 89
- Mass spectrometric imaging, MSI, tumor heterogeneity, RGB marking, proteomics, lentiviral vectors, 179
- Mass spectrometry, adenoma, biomarker, follicular, therapeutic target, 271
- Mass spectrometry, bioinformatics, *Drosophila*, liquid chromatography, ovary, proteome, proteomics, 369
- Mass spectrometry, proteomics, breast cancer, lymph node, metastasis, markers, 2D PAGE, MALDI-ToF, tumour invasion, 89
- Mass spectrophotometry, lung adenocarcinoma, quantitative proteomics, BALF, protein, biomarker, 39
- MDA-7, IL-24, endothelial cell, HECV, 243
- Menarche, genotype, menopause, triple-negative breast cancer, *XRCC3*, 359
- Menopause, genotype, menarche, triple-negative breast cancer, *XRCC3*, 359
- Meta-analysis, microarray, differentially expressed genes, DEGs, acquired drug resistance, gefitinib, 153

- Meta-analysis, PTEN, polymorphism, cancer, 263
- Metastasis, proteomics, breast cancer, lymph node, markers, 2D PAGE, MALDI-ToF, mass spectrometry, tumour invasion, 89
- Microarray, meta-analysis, differentially expressed genes, DEGs, acquired drug resistance, gefitinib, 153
- Microarray, non-small cell lung cancer, gene signature, 231
- Micro-environment, pancreatic cancer, cancer sub-population, proteomics, 49
- Micronuclei, HPV, uterine lesions, viral load, DNA damage, 67
- Migration, IL21, IL21 receptor, breast cancer, survival, invasion, 211
- Molecular Trojan horses, antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, transferrin receptor, insulin receptor, animal metastasis models, receptor-mediated endocytosis, review, 167
- MSI, mass spectrometric imaging, tumor heterogeneity, RGB marking, proteomics, lentiviral vectors, 179
- MTAI*, pituitary adenoma, staging, bone invasion, sella destruction, 113
- MTAI*, *VEGFC*, lymphatic metastasis, colorectal carcinoma, 339
- MTOR, proteomics, genomics, breast cancer, early breast cancer, targeted therapies, HER2, triple-negative, VEGF, trastuzumab, review, 385
- Mutation density, TCGA, oncoproteins, tumor suppressor proteins, cytoskeletal proteins, mutation frequency, 283
- Mutation frequency, TCGA, mutation density, oncoproteins, tumor suppressor proteins, cytoskeletal proteins, 283
- NCCR, prostate cancer, JCV, BKV, sequence analysis, 189
- Neuroblastoma, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, pancreatic cancer, phenome-genome association, open reading frames, 9
- Neuronal pathway down-regulation, doxorubicin, chemotherapy, side-effects, PAcIFIC, LC-MS/MS, breast cancer, pathway analysis, chemo brain, 347
- Non-small cell lung cancer, microarray, gene signature, 231
- Non-small-cell lung cancer, digital PCR, epidermal growth factor receptor tyrosine kinase inhibitor, T790M, 31
- O*-GlcNAcylation, breast cancer, extracellular proteins, heat-shock 70 kDa, transitional endoplasmic reticulum ATPase, 201
- Oncogenes, prostate cancer development, human Polyomavirus BK, p53 mutational rate, BKV infected prostate cells, 57
- Oncoproteins, TCGA, mutation density, tumor suppressor proteins, cytoskeletal proteins, mutation frequency, 283
- Open reading frames, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, phenome-genome association, 9
- Open reading frames, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, phenome-genome association, secretome, rule of five, tumors, 119
- Oral cancer, cigarette smoke, apoptosis, 77
- Oral cancer, cigarette smoke, cell cycle, apoptosis, 73
- Ovary, bioinformatics, *Drosophila*, liquid chromatography, mass spectrometry, proteome, proteomics, 369
- P53 mutational rate, prostate cancer development, oncogenes, human Polyomavirus BK, BKV infected prostate cells, 57
- PAcIFIC, doxorubicin, chemotherapy, side-effects, LC-MS/MS, breast cancer, pathway analysis, chemo brain, neuronal pathway down-regulation, 347
- Pancreatic cancer, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, phenome-genome association, open reading frames, 9
- Pancreatic cancer, cancer sub-population, micro-environment, proteomics, 49
- Pancreatic cancer, epigenetic alteration, promoter methylation, 21
- Pancreatic cancer, stress-induced, stress response, proteomics, 83
- Paracellular permeability, Claudin-1, claudin-5, claudin-16, clear cell renal cell carcinoma, 1
- Pathway analysis, doxorubicin, chemotherapy, side-effects, PAcIFIC, LC-MS/MS, breast cancer, chemo brain, neuronal pathway down-regulation, 347
- Phenome-genome association, Alzheimer's disease, biomarkers, body fluids, clinical variations, dark matter proteome, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, malignant melanoma, neuroblastoma, pancreatic cancer, open reading frames, 9
- Phenome-genome association, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, secretome, rule of five, tumors, 119
- Pituitary adenoma, *MTAI*, staging, bone invasion, sella destruction, 113
- Polymorphism, PTEN, cancer, meta-analysis, 263
- Post-translational modifications, eosinophil cationic protein, eosinophil-derived neurotoxin, homology, bioinformatics, 397
- Predictive factor, glioblastoma multiforme, FOX transcription factors, prognostic factor, 103
- Prognostic factor, glioblastoma multiforme, FOX transcription factors, predictive factor, 103
- Promoter methylation, epigenetic alteration, pancreatic cancer, 21
- Prostate cancer development, oncogenes, human Polyomavirus BK, p53 mutational rate, BKV infected prostate cells, 57

- Prostate cancer progression, caveolin-1, caveolin-2, 391
- Prostate cancer, JCV, BKV, NCCR, sequence analysis, 189
- Protein, lung adenocarcinoma, mass spectrophotometry, quantitative proteomics, BALF, biomarker, 39
- Proteome, bioinformatics, *Drosophila*, liquid chromatography, mass spectrometry, ovary, proteomics, 369
- Proteome, breast cancer, differential expression, biomarker identification, 251
- Proteomics, bioinformatics, *Drosophila*, liquid chromatography, mass spectrometry, ovary, proteome, 369
- Proteomics, breast cancer, lymph node, metastasis, markers, 2D PAGE, MALDI-ToF, mass spectrometry, tumour invasion, 89
- Proteomics, genomics, breast cancer, early breast cancer, targeted therapies, HER2, triple-negative, VEGF, trastuzumab, mTOR, review, 385
- Proteomics, mass spectrometric imaging, MSI, tumor heterogeneity, RGB marking, lentiviral vectors, 179
- Proteomics, pancreatic cancer, cancer sub-population, micro-environment, 49
- Proteomics, pancreatic cancer, stress-induced, stress response, 83
- Proteomics, STAT3, shRNA, Warburg effect, cancer metabolomics, 133
- PTEN, polymorphism, cancer, meta-analysis, 263
- Quantitative proteomics, lung adenocarcinoma, mass spectrophotometry, BALF, protein, biomarker, 39
- Receptor-mediated endocytosis, antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, transferrin receptor, insulin receptor, animal metastasis models, molecular Trojan horses, review, 167
- Review, antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, transferrin receptor, insulin receptor, animal metastasis models, receptor-mediated endocytosis, molecular Trojan horses, 167
- Review, biomarker discovery, biobanking, ICT tools, sample quality, 291
- Review, CAV1, breast cancer, biomarker, ionizing radiation, 143
- Review, proteomics, genomics, breast cancer, early breast cancer, targeted therapies, HER2, triple-negative, VEGF, trastuzumab, mTOR, 385
- RGB marking, mass spectrometric imaging, MSI, tumor heterogeneity, proteomics, lentiviral vectors, 179
- RNA sequencing, circulating mRNA, DASL assay, transcriptomic profiling, 223
- Rule of five, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, tumors, 119
- Sample quality, biomarker discovery, biobanking, ICT tools, review, 291
- Secretome, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, rule of five, tumors, 119
- Sella destruction, *MTA1*, pituitary adenoma, staging, bone invasion, 113
- Sequence analysis, prostate cancer, JCV, BKV, NCCR, 189
- ShRNA, STAT3, Warburg effect, cancer metabolomics, proteomics, 133
- Side-effects, doxorubicin, chemotherapy, PACIFIC, LC-MS/MS, breast cancer, pathway analysis, chemo brain, neuronal pathway down-regulation, 347
- Staging, *MTA1*, pituitary adenoma, bone invasion, sella destruction, 113
- STAT3, shRNA, Warburg effect, cancer metabolomics, proteomics, 133
- Stress response, pancreatic cancer, stress-induced, proteomics, 83
- Stress-induced, pancreatic cancer, stress response, proteomics, 83
- Survival, IL21, IL21 receptor, breast cancer, migration, invasion, 211
- T790M, digital PCR, non-small-cell lung cancer, epidermal growth factor receptor tyrosine kinase inhibitor, 31
- Targeted therapies, proteomics, genomics, breast cancer, early breast cancer, HER2, triple-negative, VEGF, trastuzumab, mTOR, review, 385
- TCGA, mutation density, oncoproteins, tumor suppressor proteins, cytoskeletal proteins, mutation frequency, 283
- Therapeutic target, adenoma, biomarker, follicular, mass spectrometry, 271
- Transcriptomic profiling, circulating mRNA, RNA sequencing, DASL assay, 223
- Transferrin receptor, antibody-effector protein fusion, antibody-antibody fusion, tropism of metastasis, insulin receptor, animal metastasis models, receptor-mediated endocytosis, molecular Trojan horses, review, 167
- Transitional endoplasmic reticulum ATPase, breast cancer, extracellular proteins, heat-shock 70 kDa, *O*-GlcNAcylation, 201
- Trastuzumab, proteomics, genomics, breast cancer, early breast cancer, targeted therapies, HER2, triple-negative, VEGF, mTOR, review, 385
- Triple-negative breast cancer, genotype, menarche, menopause, *XRCC3*, 359
- Triple-negative, proteomics, genomics, breast cancer, early breast cancer, targeted therapies, HER2, VEGF, trastuzumab, mTOR, review, 385
- Tropism of metastasis, antibody-effector protein fusion, antibody-antibody fusion, transferrin receptor, insulin receptor, animal metastasis models, receptor-mediated endocytosis, molecular Trojan horses, review, 167
- Tumor heterogeneity, mass spectrometric imaging, MSI, RGB marking, proteomics, lentiviral vectors, 179
- Tumor suppressor proteins, TCGA, mutation density, oncoproteins, cytoskeletal proteins, mutation frequency, 283
- Tumors, biomarkers, body fluids, chemoinformatics, chemogenomics, clinical variations, druggable targets, expression quantitative loci, gene ontology, genome-wide association studies, leukemia and lymphoma, open reading frames, phenome-genome association, secretome, rule of five, 119

Tumour invasion, proteomics, breast cancer, lymph node, metastasis, markers, 2D PAGE, MALDI-ToF, mass spectrometry, 89

Uterine lesions, HPV, viral load, DNA damage, micronuclei, 67

VEGF, proteomics, genomics, breast cancer, early breast cancer, targeted therapies, HER2, triple-negative, trastuzumab, mTOR, review, 385

*VEGFC*, *MTA1*, lymphatic metastasis, colorectal carcinoma, 339

Viral load, HPV, uterine lesions, DNA damage, micronuclei, 67

Warburg effect, STAT3, shRNA, cancer metabolomics, proteomics, 133

*XRCC3*, genotype, menarche, menopause, triple-negative breast cancer, 359

## Authors Index

(Figures refer to page numbers)

- Abramowski P, 179  
 Adam ML, 67  
 Akiyama Y, 133  
 Alessandroni J, 291  
 Almatroodi SA, 39  
 Anagnostopoulos AK, 369  
 Anton G, 21  
 Anzivino E, 57, 189  
 Ashizawa T, 133  
 Bacalbasa N, 21, 231  
 Baron B, 49, 83  
 Basso SMM, 385  
 Bau D-T, 359  
 Bellizzi A, 57, 189  
 Blanck G, 283  
 Bleotu C, 21  
 Botezatu A, 21  
 Bravatà V, 143  
 Cammarata FP, 143  
 Cantalice LINS, 67  
 Cavalli IJ, 89, 251  
 Champattanachai V, 201  
 Chang W-S, 359  
 Chen S, 271  
 Cheng S, 113  
 Chiara GB, 385  
 Chokchaichamnankit D, 201  
 Chuang C-L, 359  
 Coelho IEDV, 397  
 Collins AL, 39  
 Correia MTDS, 67  
 D'Alessandro R, 291  
 Da Costa GG, 251  
 Damotte D, 231  
 Darby IA, 39  
 De Andrade C, 251  
 De Lima RS, 89, 251  
 De Oliveira PCR, 397  
 Della-Morte D, 291  
 Dima SO, 21  
 Doherty R, 103  
 Du P, 1  
 Duda D, 21  
 Fawcett TJ, 283  
 Fehse B, 179  
 Ferroni P, 291  
 Foltran L, 385  
 Formica V, 291  
 Forte GI, 143  
 Fujioka T, 83  
 Gavish M, 77  
 Ge J, 263  
 Gentile V, 57, 189  
 Gilardi MC, 143  
 Gomig THB, 251  
 Guadagni F, 291  
 Hargest R, 339  
 Hata Y, 31  
 Heller M, 347  
 Hirota N, 31  
 Homma S, 31  
 Hsiao C-L, 359  
 Hsu C-M, 359  
 Hu P-S, 359  
 Hwang SG, 153  
 Iizuka A, 133  
 Ilie V, 231  
 Ishida F, 31  
 Isobe K, 31  
 Iyoda A, 31  
 Jang CS, 153  
 Ji H-X, 359  
 Jia G, 113  
 Jia W, 113  
 Jiang WG, 1, 113, 243, 339  
 Kaburaki K, 31  
 Kamibeppu T, 391  
 Kamoto T, 391  
 Katarachia S, 369  
 Kaviski R, 89, 251  
 Kim JK, 153  
 Kim SY, 153  
 Kim YR, 153  
 Kitagawa T, 49, 83  
 Kjeldsen E, 301  
 Klepetko W, 231  
 Kobayashi H, 31  
 Komiyama M, 133  
 Konstantakou EG, 369  
 Kraus O, 179  
 Krayzler E, 73, 77  
 Kruzliak P, 347  
 Kukulj C, 251  
 Kume A, 133  
 Kuramitsu Y, 49, 83  
 Kusuhara M, 133  
 Kwon K, 153  
 Lai X, 271  
 Lane H-Y, 359  
 Lapenda JC, 67  
 Laszlo V, 231  
 Lee YS, 153  
 Li J, 339  
 Liao C-H, 359  
 Liu X, 113  
 Lopes DDO, 397  
 Lu R, 113  
 Lumachi F, 385  
 Luo J, 263  
 Madhusudan S, 103  
 Maehara S-I, 83  
 Maehara Y, 83  
 Makino T, 31  
 Mansuet-Lupo A, 231  
 Manta AK, 369  
 Martin TA, 1, 113, 243  
 McDonald CF, 39  
 Men W, 1  
 Messa C, 143  
 Milioli HH, 89  
 Minafra L, 143  
 Mischitelli M, 57, 189  
 Miyata H, 133  
 Mpakou VE, 369  
 Mukai S, 391  
 Myeong HS, 153  
 Nagler RM, 73, 77  
 Nakamura K, 49, 83  
 Nanni U, 291  
 Narayanan R, 9, 119  
 Nastase A, 21  
 Netsirisawan P, 201  
 Niewöhner J, 167  
 Noh YH, 153  
 Oliveira NCDS, 89  
 Omiya M, 133  
 Otsuka H, 31  
 Owen S, 243  
 Palmirota R, 291  
 Papassideri IS, 369  
 Park TH, 153  
 Parry ML, 283  
 Pereira MC, 397  
 Perry C, 103  
 Petrovic M, 347  
 Pietropaolo V, 57, 189  
 Pini C, 67  
 Popescu I, 21, 231  
 Pouniotis DS, 39  
 Pucci M, 143  
 Regnard JF, 231  
 Ribeiro EMSF, 89, 251  
 Riecken K, 179  
 Riondino S, 291  
 Robertson E, 103  
 Rodio DM, 57, 189  
 Rohn S, 179  
 Roselli M, 291  
 Ruge F, 1, 243  
 Sabo J, 347  
 Sagioglou NE, 369  
 Sakamoto S, 31  
 Salciccia S, 189  
 Sanders AJ, 113, 243  
 Sano G, 31  
 Satherley L, 339  
 Schlüter H, 179  
 Sciarra A, 57, 189  
 Shibuya K, 31  
 Simillion C, 347  
 Sousa KS, 89, 251  
 Spila A, 291  
 Srisomsap C, 201  
 Stravopodis DJ, 369  
 Su C-H, 359  
 Sugie S, 391  
 Sugino K, 31  
 Sun P-H, 339  
 Svasti J, 201  
 Takai Y, 31  
 Tan Y, 243  
 Tica V, 231  
 Tiefenthaler G, 167  
 Tochigi N, 31  
 Torres RA, 67  
 Tsai C-W, 359  
 Tsangaris GT, 369  
 Tsioka MM, 369  
 Tsukino H, 391  
 Túlio S, 67  
 Urakami K, 133  
 Urban CDA, 89  
 Veenman L, 77  
 Velentzas AD, 369  
 Velentzas PD, 369  
 Wang Y, 263  
 Weidle UH, 167  
 Yamaguchi K, 133  
 Yamasaki K, 391  
 Yan Y, 1  
 Yang H, 263  
 Yang X, 113  
 Ye L, 339  
 Yu H, 113  
 Yueh T-C, 359  
 Zhang N, 1  
 Zhang Y, 243  
 Zhang Z, 339  
 Zhu J, 113

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org), [www.cgp.iiarjournals.org](http://www.cgp.iiarjournals.org)

**Publication Data:** CANCER GENOMICS & PROTEOMICS (CGP) is published online-only with open access bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

**Copyright:** Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org) (Editorial Office), [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org) (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

**Annual Subscription.** CANCER GENOMICS & PROTEOMICS is converted to an online-only open access journal from January 2014 (Volume 11)

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.